Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer

Cancer Research and Treatment

Volumn 49, Issue 2, 2017, Pages 399-407

  Song, In Hye ^a   Heo, Sun Hee ^a   Bang, Won Seon ^a   Park, Hye Seon ^a   Park, In Ah ^a   Kim, Young Ae ^a   Park, Suk Young ^a   Roh, Jin ^a   Gong, Gyungyub ^a   Lee, Hee Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Immunohistochemistry; Prognosis; Tertiary lymphoid structure; Triple negative breast neoplasms

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; CXCL13 CHEMOKINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EOSIN; HEMATOXYLIN; BIOLOGICAL MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CELL DENSITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOTHELIUM CELL; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; TERTIARY LYMPHOID STRUCTURE; TRIPLE NEGATIVE BREAST CANCER; VENULE; AGED; BIOPSY; CANCER GRADING; CANCER STAGING; FEMALE; GENE EXPRESSION PROFILING; IMMUNOLOGY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; BIOPSY; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TERTIARY LYMPHOID STRUCTURES; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 85017368602     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2016.215     Document Type: Article

References (28)

1. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. 1992;28A:859-64.
2. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-10.
3. Lee HJ, Seo JY, Ahn JH, Ahn SH, Gong G. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2013;16:32-9.
4. Ahn SG, Jeong J, Hong S, Jung WH. Current Issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer. J Pathol Transl Med. 2015;49:355-63.
5. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptornegative breast cancer. Breast Cancer Res. 2011;13:R126.
6. Stagg J, Allard B. Immunotherapeutic approaches in triplenegative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013;5:169-81.
7. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, et al. Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011;71: 5678-87.
8. Lee HJ, Kim JY, Park IA, Song IH, Yu JH, Ahn JH, et al. Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant trastuzumab. Am J Clin Pathol. 2015; 144:278-88.
9. Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P, et al. High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology. 2012;1:829-39.
10. Girard JP, Moussion C, Forster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol. 2012;12:762-73.
11. Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007;56:1459-69.
12. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with nonsmall-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26:4410-7.
13. Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in earlystage colorectal cancers. Clin Cancer Res. 2014;20:2147-58.
14. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et al. CD4(+) follicular helper T cell infiltration predictsbreast cancer survival. J Clin Invest. 2013;123:2873-92.
15. Lee HJ, Lee JJ, Song IH, Park IA, Kang J, Yu JH, et al. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Breast Cancer Res Treat. 2015;151:619-27.
16. Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 2012;33:297-305.
17. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29: 1949-55.
18. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14:R48.
19. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68: 5405-13.
20. Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014;20:5995-6005.
21. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414-22.
22. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259-71.
23. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26:317-25.
24. Bellone M, Calcinotto A. Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol. 2013;3:231.
25. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012;132:545-53.
26. Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109:2 705-13.
27. Kang H, Cheong H, Cho MS, Koo H, Han WS, Lee KE, et al. Significance of Foxp3 positive regulatory T cell and tumor infiltrating T lymphocyte in triple negative breast cancer. Korean J Pathol. 2011;45:53-61.
28. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185:4977-82.